Zoledronic acid early increases serum osteoprotegerin in early stage multiple myeloma.

被引：0
|
作者：
Gozzetti, Alessandro [1 ]
Martini, Giuseppe [1 ]
Salvadori, Stefania [1 ]
Gennari, Luigi [1 ]
Avanzati, Annalisa [1 ]
Franci, Beatrice [1 ]
Carnpagna, Maria Stella [1 ]
Nuti, Ranuccio [1 ]
Lauria, Francesco [1 ]
机构：
[1] Univ Siena, I-53100 Siena, Italy
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3588.3588
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3588
引用
收藏
页码：1025A / 1025A
页数：1
相关论文
共 50 条
  • [21] Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma
    Yu, Andrew Peng
    Bensimon, Arielle G.
    Marynchenko, Maryna
    Wu, Eric Qiong
    Namjoshi, Madhav
    Guo, Amy
    Ericson, Solveig G.
    Raje, Noopur
    BLOOD, 2010, 116 (21) : 816 - 816
  • [22] Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma
    Depil, S
    Mathiot, C
    Leleu, X
    Moreau, AS
    Faucompré, JL
    Hennache, B
    Bauters, F
    Bataille, R
    Facon, T
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (05) : 706 - 707
  • [23] Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients
    Corso, A
    Arcaini, L
    Mangiacavalli, S
    Astori, C
    Orlandi, E
    Lorenzi, A
    Passamonti, F
    Klersy, C
    Pascutto, C
    Canevari-Sciorati, A
    Lazzarino, M
    HAEMATOLOGICA, 2001, 86 (04) : 394 - 398
  • [24] Safety and efficacy of zoledronic acid in multiple myeloma
    Tanimoto, Tetsuya
    Matayoshi, Tetsutaro
    Yagasaki, Fumiharu
    Takeuchi, Kengo
    Kami, Masahiro
    LANCET, 2011, 377 (9784): : 2178 - 2178
  • [25] Predictors of early relapse following autografting for myeloma.
    Raje, N
    Powles, R
    Horton, C
    Kulkarni, S
    Eisen, T
    Middleton, G
    Treleaven, J
    BLOOD, 1996, 88 (10) : 510 - 510
  • [26] Routine Use of Zoledronic Acid in Early-Stage Breast Cancer
    Harnden, Kathleen
    Blackwell, Kimberly
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (04): : 480 - 486
  • [27] The effect of increasing zoledronic acid dose and infusion rate on pharmacokineties, pharmacodynamics, and renal function in patients with multiple myeloma.
    Berenson, J
    Major, P
    Ravera, C
    Bilic, S
    Schran, H
    BLOOD, 2004, 104 (11) : 316B - 316B
  • [28] Zoledronic acid by carcinoma of the prostate - Serum marker for early identification of metastases
    不详
    UROLOGE, 2007, 46 (08): : 971 - 972
  • [29] Treatment of bortezomib increases osteoblast function in patients with multiple myeloma.
    Heider, U
    Kaiser, M
    Müller, C
    Schulz, CO
    Jakob, C
    Zavrski, I
    Eucker, J
    Sterz, J
    Kleeberg, L
    Possinger, K
    Sezer, O
    BLOOD, 2005, 106 (11) : 965A - 965A
  • [30] Comparison of Skeletal Complications and Treatment Patterns Associated With Early vs. Delayed Zoledronic Acid Therapy in Multiple Myeloma
    Wu, Eric Q.
    Bensimon, Arielle G.
    Marynchenko, Maryna
    Namjoshi, Madhav
    Guo, Amy
    Yu, Andrew P.
    Ericson, Solveig G.
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (04): : 326 - 335
12345